brentuximab vedotin
seagen,takeda
['cml', 'echelon-1']
 pfs is a valid endpoint for studies on primary therapy for chl. &gt;10,000 pts, in ghsg trials. also other, such as echelon-1.
high corr of pfs and os. pt and trial level. os can be predicted from pfs.
very thorough and convincing analysis. #17icml 
Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.